Background: In 1966, first description of a "Steroid-Responsive Encephalopathy Associated with autoimmune Thyroiditis (SREAT)" syndrome was described. Since then, lots of cases emerged with two major kinds of presentations: "vasculitic" and "diffuse progressive". Patients respond variably to corticoids. Methotrexate, plasmatic exchange or intravenous imunoglobulins (IvIG) have only been anecdotically used.
BACKGROUND
The first description of a "Steroid-Responsive Encephalopathy Associated with autoimmune Thyroiditis (SREAT)" syndrome was dated from 1966 [1] . In 1974, two new cases were described [2] . All three presented with episodic subacute, progressive encephalopathy with cortico-sensitive remissions. Since then, lots of cases emerged with two major kinds of presentations: "vasculitic" and "diffuse progressive". However, in some peculiar presentations, monosymptomatic cases have been described as isolated progressive myelopathy, psychosis, cerebellopathy, paraparesthesia, epilepsy, headache or dementia. Typically, the diffuse progressive form of SREAT showed progressive dementia accompanied by depressive disorders, cerebellopathy and extrapyramidal signs [3] . Progressive aphasia, apraxia, amnesia, or all of them are other presentations of the syndrome with asthenia and headaches as classical supporting symptoms.
CASE REPORT
In early 2000, a French-speaking, right handed, 63 years old commercial representative, presented with mild words finding difficulties evolving for 5 years. His weight was 70 kg and he was 180 cm tall. He smoked 25 cigarettes/day. He lost appetite and was tired despite sleeping 10 hours/day for *Address correspondence to this author at the Hôpital Erasme, Service de Neurologie; 808 route de Lennik, 1070 Bruxelles, Belgium; Tel: +32-2-555-46-22; Fax: +32-2-555-39-42; E-mail: jbier@ulb.ac.be 3 years. He drove his car more cautiously than before and complained about difficulties in parking. His family history revealed various cancers with mother deceased at 94 years, father at 76 while his brother at 58. Personal medical history consisted in arteriopathy requiring left femoral percutaneal dilatation with stenting in 1996, appendicectomy and chirurgically treated anal fistula. He presented hypercholesterolemia, hypertension and seborrhoeic hyperkeratosis. He was treated with Amlodipine 5 mg/day; acetylsalicylic acid 100 mg/day and pravasine 20 mg/day. He also tried pyracetam 2400 mg/day for a few months but stopped it for subjective inefficiency. He presented bradypsychia with a MMSE score of 28/30. A diagnosis of depression was proposed and treated with citalopram 20 mg/day for four months with none observed benefit. At this time, he fell regularly asleep while eating or watching TV. Cerebral Ct scan showed no structural lesion. Multiple electroencephalographies (EEG) were normal with an occipital alpha rhythm of 8-9 Hz. Blood investigations were all normal including sedimentation rate, C-reactive protein, haematology, chemistry, lactate, coagulation, lipids, liver functions, renal function, calcium, magnesium, thyroid stimulating hormone, riboflavine, folates, antinuclear antibodies, ANCA, proteins and immune-electrophoresis, cholestéanol, long chain fatacids, amino-acids profile, ceruloplasmine & cupper, iron function, syphilitic serology, HIV serology, HCV serology, HBV serology, ... Urinary examination was normal too with no protein and no porphobilinogen or delta-aminolevulinic acid. During the next three years, he presented left extinction, extra-pyramidal gait, followed by spontaneous myoclo-nies and increasing bradykinesia. In August 2002 ophtalmoscopic examination was normal. Left visual field was first impaired but controlled two months later normal. Cervical ultrasonography showed carotidal intimae thickening evaluated in its maximal broad to 1,8 mm. Transthoracic echocardiography and 24 hour's electrocardiogram were both normal. Asthenia progressed and audition decreased due to a beginning presbyacousy revealed by audiometry. A neuropsychological examination showed a severe cognitive alteration of the visuospatial processing (see Table 1 ) with abnormal performance in visuospatial working memory (blocktapping test), visual-constructive skills (Rey's complexe figure), visual selective attention (3 matrixes), visuospatial reasoning (PM38). We also found an alteration of executive functions (Stroop test) and mental calculation. Pictures naming, verbal episodic memory and verbal fluencies were globally preserved. In December 2002, left elbow rigidity was evaluated by the UPDRS quotation to and to 2/4 on the right. Dermal biopsy showed chronicle lesions of eczema with lymphocytic infiltration. Two lumbar punctures were normal. The first one showed no leucocytes and nine red cells by millimetre cube. The second one demonstrated one polyneutrophylic and 115 red cells by millimetre cube. There was no malignancy cell. Proteins, glycorachy and lactic acid were systematically normal. There was no band on electrofocusing and albumin-immunoglobulin index was normal. Brain MRI was normal despite a diffuse atrophy with a slight predominance in the posterior areas and no focal lesion (Fig. 1) .
In view of progressive dressing apraxia, left neglect, myoclonies and unsymmetrical extrapyramidal signs, a diagnosis of Posterior Cortical Atrophy probably due to CorticoBasal Degeneration was set up. A 18 FDG-PET-scan of the brain showed predominantly posterior cortical hypometabolism, suggestive of a degenerative disorder. In order to confirm the visual PET data evaluation, PET data were analyzed using a voxel-based method, Statistical Parametric Mapping (SPM99) (Fig. 1) . Treatment by rivastigmine 6 mg/day was then associated with a stabilisation of 8 months. Memantine 20 mg/day was added helping view of increasing dressing apraxia ( Table 1) . In April 2004, Bromocriptine 10 mg/day (Fig. 2) . Brain CT-scan and MRI both showed cortical atrophy with no structural lesion (Fig. 1) 
DISCUSSION
The SREAT syndrome is heterogeneous and includes various descriptions. There are, even at least, three cases suffering from peripheral neuropathies associated with autoimmune thyroiditis [4] [5] [6] . In all described cases, elevated levels of antibodies are the only constancy. Even cerebrospinal fluid analysis remains controversial. Some studies suggest an intrathecal synthesis of autoantibodies while others argue against it [3] . Usually, EEG is non-specifically abnormal, brain CT scan or MRI may be normal and PET or SPECT imageries seem not more specific [3] . One unconfirmed case of SREAT's MRI-spectroscopy revealed frontal reduction of N-acetylaspartate (arguing for a neuronal disease) with an increase of cholines (arguing for a glial one), disappearing after treatment with corticoids [7] . All but one of the few reported pathological examinations, revealed perivenular and arteriolar, predominantly T-type, lymphocytic infiltration within the leptomeninges and parenchyma [3] . The patient described by Oide et al. had negative autopsy [8] . Similarly, the therapeutic response may vary a lot. Some patients improved spontaneously with or without relapses [3] . Flunarizine helped in one case reported while methotrexate, plasmatic exchange or intravenous immunoglobulins (IvIG) have only been anecdotically used [3, 9] . To date, pathogenic mechanisms of SREAT remain unclear. A direct impact of the Thyrotropin-releasing hormone has even been evoked. Occurring of cerebral oedema too [1] , sometimes with a swelling effect on MRI [10] . Vasculitic phenomenon has regularly been described with myo-vascular modifications [10] , immune-complex implication [2] or cerebral arterial calibre variations [11] . A mitochondrial origin has even been proposed [12] . More recently, a high prevalence of serum autoantibodies against amino terminal's alpha-enolase has been described in SREAT with an excel Fig. (2) . EEG showing frontal intermittent rhythmic delta activity (July 2005). 1 lent specificity (80%) [9] . In 1991, Shaw et al. proposed the set of new SREAT diagnostic criteria [13] . These were revised in 1999 by Peschen-Rosin et al. as the presence of recurrent myoclonies, epilepsy, psychiatric troubles or any focal neurological signs associated with three of the five following points: 1/ abnormal EEG; 2/ elevated antithyroid antibodies; 3/ elevated proteinorachy; 4/ dramatic improvement with corticoids; 5/ no structural explication on MRI [14] . However, as discussed by Ferracci et al. [3] , since 1999, lots of presentations have been described. Moreover, it could be interesting to reconsider the absolute necessity of antibodies in these criteria. Identically, thyroid function could be considered in these criteria. In our case, as classically described, thyroid function lab test was only once and lately proved to be abnormal. Clearly, a high titre of antithyroid antibodies associated with progressive encephalitis does not necessarily implicate a causal relationship. However, our case fulfil diagnostic criteria of SREAT with the presence of recurrent myoclonies, psychiatric troubles and multiple focal neurological signs associated with an abnormal EEG (Fig. 2) , an elevated antithyroid antibodies and no structural explication on MRI. Moreover, the history of his progressive encephalopathy and his laboratory examinations exclude any congenital aetiology. No structural lesions on brain imageries exclude vascular and traumatic aetiologies. Infectious and inflammatory origins are ruled out by blood exams and multiple lumbar punctures. Degenerative disorders and especially Posterior Cortical Atrophy (PCA) cannot be completely excluded. However, these degenerative syndromes are not characterized by its unequivoque pathology. Thus, SREAT and PCA are compatible and certainly not respectively exclusive. Creutzfeldt-Jakob disease is improbable in view of the clinical evolution and of EEGs. Clinic, MRI and biology excluded paraneoplastic and nonparaneoplastic limbic encephalitis [15] . Finally, our case, as others before [16] , argues against definitive efficacy of corticosensitivity in SREAT. It could be said that, in most cases, SREAT would be diagnosed when antibodies are found in the absence of other well-defined aetiologies. Systematic report of all suspected cases and the study of their therapeutic response would be useful to better understand SREAT syndrome.
CONCLUSION
This case of clinical worsening after immunotherapy highlights the necessity to cautiously interprete the current diagnostic criteria and to report all cases of suspect SREAT. Moreover, its responses to therapeutics require further assessment.
